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Objective: The SNP309 polymorphism (T-G) in the promoter of MDM2 gene has been reported to be associated
with enhanced MDM2 expression and tumor development. Studies investigating the association between MDM2
SNP309 polymorphism and endometrial cancer risk reported conflicting results. We performed a meta-analysis of all
available studies to explore this association.
Methods: All studies published up to August 2013 on the association between MDM2 SNP309 polymorphism and
endometrial cancer risk were identified by searching electronic databases PubMed, Web of Science, EMBASE, and
Chinese Biomedical Literature database (CBM). The association between the MDM2 SNP309 polymorphism and
endometrial cancer risk was assessed by odds ratios (ORs) together with their 95% confidence intervals (CIs).
Results: Eight case–control studies with 2069 endometrial cancer cases and 4546 controls were identified. Overall,
significant increase of endometrial cancer risk was found when all studies were pooled in the meta-analysis (GG vs.
TT: OR = 1.464, 95% CI 1.246–1.721, P < 0.001; GG vs. TG + TT: OR = 1.726, 95% CI 1.251–2.380, P = 0.001; GG + TG vs.
TT: OR = 1.169, 95% CI 1.048–1.304, P = 0.005). In subgroup analysis by ethnicity and HWE in controls, significant increase
of endometrial cancer risks were observed in Caucasians and studies consistent with HWE. In subgroup analysis according
to study quality, significant associations were observed in both high quality studies and low quality studies.
Conclusions: This meta-analysis suggests that MDM2 SNP309 polymorphism contributes to endometrial cancer
susceptibility, especially in Caucasian populations. Further large and well-designed studies are needed to confirm
this association.
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Endometrial cancer is one of the most common gyneco-
logic cancers in developed countries [1,2]. Although its
incidence rates are up to ten times higher in industrialized
countries when compared to Asia or Africa, its prevalence
has also been increasing in developing countries during
the last decades [2]. As with all solid tumors, endometrial
cancer is a heterogeneous disease with complex genetic
and environmental influences. It has been suggested that* Correspondence: qinxue919@126.com; lis8858@126.com
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stated.environmental risk factors such as obesity and overexpos-
ure to endogenous or exogenous hormones may be in-
volved in the pathogenesis of endometrial cancer [3,4]. In
addition, predisposition to endometrial cancer is mediated
by genetic factors including both germinal and somatic al-
terations as well as genetic polymorphisms [5,6].
The murine double minute-2 (MDM2) is a key negative
regulator of the P53 tumor suppressor pathway which has
been suggested to be implicated in a variety of cancers [7].
Evidence shows that MDM2 can bind directly to P53 pro-
tein and inhibit its activity, thus resulting in its degradation
via the ubiquitination pathway [8]. A single nucleotide
polymorphism (SNP) in the promoter region of MDM2,
SNP T309G (rs2279744), has been identified and wastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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a greater affinity for the SP1 transcription factor. Conse-
quently, individuals carrying the GG genotype of the
MDM2 SNP309 polymorphism were found to have higher
MDM2 levels, which led to attenuation of the TP53 path-
way and acceleration of tumor formation in humans [9]. It
was reported that the increase in MDM2 results in direct
inhibition of p53 transcriptional activity, enabling damaged
cells to escape the cell-cycle checkpoint and become
carcinogenic [10]. Hence, it is biologically reasonable to
hypothesize a potential relationship between the MDM2
SNP309 polymorphism and endometrial cancer risk.
Over the last two decades, a number of molecular epi-
demiological studies have been conducted to investigate
the association between the MDM2 SNP309 polymorph-
ism and endometrial cancer risk, but the results remain in-
consistent. Several studies have previously suggested that
the MDM2 SNP309 polymorphism was associated with
an increased risk of endometrial cancer [11-13]. However,
other studies have failed to confirm such an association
[14,15]. In addition, a meta-analysis including six studies
by Li et al. [16] found that the GG genotype of MDM2
SNP309 polymorphism was significantly associated with
the increased endometrial cancer risk. However, they in-
cluded two studies containing overlapping data [13,17] in
their meta-analysis, which might make their conclusions
questionable. As new studies emerge [15,18,19], to provide
the most comprehensive assessment of the associations
between the MDM2 SNP309 polymorphism and endomet-




We conducted a comprehensive literature search in
PubMed, Web of Science, EMBASE, and Chinese Biomed-
ical Literature (CBM) databases up to August 01, 2013
using the following search strategy: (“endometrial cancer”)
and (“Murine double minute 2”, or “MDM2”). There was
no restriction on time period, sample size, population, lan-
guage, or type of report. All eligible studies were retrieved
and their references were checked for other relevant stud-
ies. The literature retrieval was performed in duplication by
two independent investigators (Qiliu Peng and Cuiju Mo).
Inclusion and exclusion criteria
Studies included in the meta-analysis were required to
meet the following criteria: (1) Case–control studies which
evaluated the association between MDM2 SNP309 poly-
morphism and endometrial cancer risk; (2) used an unre-
lated case–control design; (3) had an odds ratio (OR) with
95% confidence interval (CI) or other available data for esti-
mating OR (95% CI); and (4) the control population did not
contain malignant tumor patients. Conference abstracts,case reports, editorials, review articles, and letters were ex-
cluded. When multiple publications reported on the same
or overlapping data, we chose the most recent or largest
population. When a study reported the results on different
subpopulations, we treated it as separate studies in the
meta-analysis.
Data extraction
Two reviewers (Qiliu Peng and Cuiju Mo) independently
reviewed and extracted data from all eligible studies.
Data extracted from eligible studies included the first au-
thor, year of publication, country of origin, ethnicity,
genotyping method, matching criteria, source of control,
endometrial cancer confirmation criteria, total number
of cases and controls and genotype frequencies of cases
and controls. Ethnic backgrounds were categorized as
Caucasian and Asian. To ensure the accuracy of the ex-
tracted information, the two investigators checked the
data extraction results and reached consensus on all of
the data extracted.
Methodological quality assessment
Methodological quality was independently assessed by
two reviewers (Qiliu Peng and Cuiju Mo), according to a
set of predefined criteria (Additional file 1: Table S1)
based on the scale of Thakkinstian et al. [20]. The re-
vised criteria cover the representativeness of cases, the
credibility of controls, ascertainment of endometrial can-
cer, genotyping examination, Hardy-Weinberg equilib-
rium (HWE) in the control population, and association
assessment. Disagreements were resolved by consensus.
Scores ranged from 0 (lowest) to 12 (highest). Articles
with scores less than 8 were considered “low-quality”
studies, whereas those with scores equal to or higher
than 8 were considered “high-quality” studies.
Statistical analysis
The strength of the association between MDM2 SNP309
polymorphism and endometrial cancer risk was assessed
by odds ratios (ORs) with 95% confidence intervals (CIs).
The significance of the pooled OR was determined by Z
test and a p value of less than 0.05 was considered signifi-
cant. The association of MDM2 SNP309 polymorphism
with endometrial cancer risk was assessed using additive
models (GG vs. TT and TG vs. TT), recessive model (GG
vs. TG+ TT), and dominant model (GG + TG vs. TT).
The χ2 based Q test and I2 statistics were used to as-
sess the heterogeneity among studies [21,22]. If the re-
sult of the Q test was PQ < 0.1 or I
2 ≥ 50%, indicating the
presence of heterogeneity, a random-effects model (the
DerSimonian and Laird method) was used to estimate
the summary ORs [23]; otherwise, when the result of the
Q test was PQ ≥ 0.1 and I
2 < 50%, indicating the absence
of heterogeneity, the fixed-effects model (the Mantel–
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of heterogeneity among studies, we performed logistic
metaregression and subgroup analyses. The following study
characteristics were included as covariates in the meta-
regression analysis: genotyping methods (PCR-RFLP vs.
not PCR-RFLP), ethnicity (Caucasians vs. Asians), source
of controls (Hospital-based vs. Population-based), quality
scores (High-quality vs. Low-quality), HWE status (Yes vs.
No), and endometrial cancer confirmation (pathologically
or histologically confirmed vs. other diagnosis criteria).
Subgroup analyses were conducted by ethnicity, study
quality, and HWE in controls. Galbraith plots analysis was
performed for further exploration of the heterogeneity.
Sensitivity analysis was performed by sequential omis-
sion of individual studies. Publication bias was evaluated
using a funnel plot and Egger’s regression asymmetry
test [25]. The distribution of the genotypes in the con-
trol population was tested for HWE using a goodness-
of-fit χ2 test. All analyses were performed using Stata
software, version 12.0 (Stata Corp., College Station, TX).
Result
Study characteristics
With our search criterion, 35 individual records were
found, but only ten full-text publications were prelimin-
arily identified for further detailed evaluation. According
to the exclusion criteria, three publications were ex-
cluded including one publication containing overlapped
data [17], one was a meta-analysis [16], and one was a
letter [26]. Manual search of references cited in the pub-
lished studies did not reveal any additional articles. As a
result, a total of seven relevant studies met the inclusion
criteria for the meta-analysis [11-15,18,19]. Among them,
one of the eligible studies contained data on two different
ethnic groups [12], and we treated it independently. There-
fore, a total of eight separate comparisons including 2069
endometrial cancer cases and 4546 controls were finally
included in our meta-analysis. The main characteristics of
the studies are presented in Table 1. Of all the eligibleTable 1 Characteristics of studies included in this meta-analy
First author
(Year)




Walsh [11] America Caucasian 73/79 PCR-RFLP
Terry NHS [12] America Caucasian 394/948 PCR-RFLP A
Terry WHS [12] America Caucasian 122/368 PCR-RFLP A
Ashton 2009 [14] Australia Caucasian 191/291 TaqMan Assay
Nunobiki [13] Japan Asian 102/95 PCR-RFLP
Zajac [18] Poland Caucasian 152/100 PCR-RFLP
Knappskog [19] Norway Caucasian 910/2465 TaqMan Assay
Yoneda [15] Japan Asian 125/200 PCR-RFLP
EC, Endometrial cancer; HC, Histologically confirmed; PC, Pathologically confirmed;
HWE, Hardy–Weinberg equilibrium in control population; PCR–RFLP, Polymerase chstudies, six were conducted in Caucasian populations, and
two were in Asians. Four studies were population–based
and four were hospital–based studies. All studies used vali-
dated methods including PCR-RFLP, TaqMan assay to
genotype the MDM2 SNP309 polymorphism. The endo-
metrial cancer cases were histologically or pathologically
confirmed in five of the eligible studies. The genotype dis-
tribution of the controls in one study was not consistent
with HWE [13].
Meta-analysis
The results of the association between MDM2 SNP309
polymorphism and endometrial cancer risk were shown
in Table 2. Overall, significant elevated endometrial can-
cer risk was found when all studies were pooled into the
meta-analysis (GG vs. TT: OR = 1.464, 95% CI 1.246–
1.721, P < 0.001, Figure 1; GG vs. TG + TT: OR = 1.726,
95% CI 1.251–2.380, P = 0.001; GG + TG vs. TT: OR =
1.169, 95% CI 1.048–1.304, P = 0.005). In subgroup ana-
lysis by ethnicity, significant increased endometrial can-
cer risk was found in Caucasians (GG vs. TT: OR =
1.602, 95% CI 1.208–2.125, P = 0.001; GG vs. TG + TT:
OR = 1.748, 95% CI 1.161–2.632, P = 0.007; GG + TG vs.
TT: OR = 1.173, 95% CI 1.047–1.315, P = 0.006) but not
in Asians. In stratified analysis by HWE in controls, signifi-
cant increased endometrial cancer risk was also observed
in studies consistent with HWE (GG vs. TT: OR = 1.473,
95% CI 1.249–1.737, P < 0.001, Figure 2; GG vs. TG +TT:
OR = 1.471, 95% CI 1.267–1.707, P < 0.001; GG+TG vs.
TT: OR = 1.184, 95% CI 1.060–1.323, P = 0.003). When
stratified by study quality, significant associations were
found in both high quality studies and low quality studies.
Test of heterogeneity
Statistical significant heterogeneity among studies was
observed in the association analysis between the MDM2
SNP309 polymorphism and endometrial cancer risk in
the overall populations (GG vs. GT + TT: PQ < 0.001;











NA HB NA 5.5 0.650
ge, menopausal status PB PC 11 0.642
ge, menopausal status PB PC 11 0.180
Age, gender PB HC 9 0.493
NA HB HC 5 0.018
NA HB HC 6.25 0.701
NA HB NA 8 0.406
NA PB NA 9 0.910
NA, Not available; PB, Population–based; HB, Hospital–based;
ain reaction-restriction fragment length polymorphism.
Table 2 Meta-analysis of MDM2 309 T/G polymorphism and endometrial cancer risk
Analysis No. of
studies
Homozygote (GG vs. TT) Heterozygote (TG vs. TT) Dominant model (GG + TG vs. TT) Recessive model (GG vs. TG + TT)
OR (95% CI) P/PQ OR (95% CI) P/PQ OR (95% CI) P/PQ OR (95% CI) P/PQ
Overall 8 1.464 (1.246-1.721) 0.000/0.175 1.073 (0.955-1.205) 0.238/0.312 1.169 (1.048-1.304) 0.005/0.759 1.726 (1.251-2.380) 0.001/0.000
Ethnicity
Caucasian 6 1.453 (1.225-1.724) 0.000/0.181 1.084 (0.960-1.223) 0.192/0.521 1.173 (1.047-1.315) 0.006/0.900 1.748 (1.161-2.632) 0.007/0.000
Asian 2 1.560 (0.943-2.581) 0.083/0.542 0.855 (0.358-2.038) 0.723/0.156 1.047 (0.531-2.064) 0.894/0.113 0.981 (0.813-1.525) 0.212/0.494
Study quality
High quality 5 1.376 (1.157-1.637) 0.000/0.569 1.120 (0.992-1.264) 0.068/0.883 1.174 (1.047-1.316) 0.006/0.929 1.495 (1.293-1.728) 0.002/0.368
Low quality 3 2.264 (1.421-3.607) 0.001/0.191 0.748 (0.428-1.023) 0.121/0.705 1.118 (0.766-1.631) 0.563/0.195 3.124 (2.146-4.548) 0.000/0.130
HWE in controls
Yes 7 1.473 (1.249-1.737) 0.000/0.119 1.093 (0.971-1.230) 0.141/0.601 1.184 (1.060-1.323) 0.003/0.907 1.471 (1.267-1.707) 0.000/0.000
No 1 1.268 (0.549-2.928) 0.579/— 0.528 (0.254-1.100) 0.088/— 0.708 (0.353-1.421) 0.332/— 1.830 (0.974-3.830) 0.067/—
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Figure 1 Forest plots of MDM2 SNP309 polymorphism and endometrial cancer risk in subgroup analysis by ethnicity using a fixed-effect
model (additive model GG vs. TT).
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http://www.jeccr.com/content/32/1/85performed metaregression and subgroup analyses. Metar-
egression analysis of data showed that the ethnicity, study
quality, and HWE status were the sources which contrib-
uted to heterogeneity. Subsequently, we performed sub-
group analyses stratified by ethnicity, study quality, and
HWE status. However, heterogeneity still existed among











Figure 2 Forest plots of MDM2 SNP309 polymorphism and endometr
model (additive model GG vs. TT).consistent with HWE (GG vs. GT + TT: PQ < 0.001). To
further investigate the heterogeneity, we performed
Galbraith plots analysis to identify the outliers which
might contribute to the heterogeneity. Our results showed
that the study Zajac et al. [18] was the outlier in the overall
populations (Figure 3). All I2 values decreased obviously




















ial cancer risk in studies consistent with HWE using a fixed-effect
Figure 3 Galbraith plots of MDM2 SNP309 polymorphism and endometrial cancer risk in the overall populations (Recessive model GG
vs. TG + TT). The study of Zajac et al. was spotted as outlier.
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GT +TT: PQ = 0.241), Caucasians (GG vs. GT+TT: PQ =
0.179), and studies consistent with HWE (GG vs. GT+
TT: PQ = 0.260). However, the significance of the summary
ORs for MDM2 SNP309 polymorphism in the overall
population and subgroup analyses were not influenced by
omitting the study by Zajac et al. [18].
Sensitivity analysis
Sensitivity analysis was performed to assess the influence
of each individual study on the pooled OR by sequential
removal of individual studies. The results suggested that
no individual study significantly affected the pooled ORs,
indicating that our results were robust and reliable.Figure 4 Funnel plots for publication bias of the meta-analysis on the
endometrial cancer risk of the overall populations (additive model GGPublication bias
Begg’s funnel plot and Egger’s test were performed to ac-
cess the publication bias of literatures in this meta-
analysis. The shapes of Funnel plot did not reveal obvi-
ous evidence of asymmetry, and all the p values of
Egger’s tests were more than 0.05, providing statistical
evidence of the funnel plots’ symmetry (Figure 4). Thus,
the results above suggested that publication bias was not
evident in this meta-analysis.
Discussion
It has been shown that estrogen signaling affect MDM2
expression levels through an interaction of estrogen recep-
tor (ER) with a region of the MDM2 promoter [27,28].association between MDM2 SNP309 polymorphism and
versus TT).
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ER binds and leads to transcription of the MDM2 gene
[29]. Furthermore, the G allele of SNP309 increases the af-
finity of the MDM2 promoter for the transcription factor
Sp1 [27]. Sp1 is a co-transcriptional activator of many hor-
mone receptors, including ER [30] and is known to par-
ticipate in estrogen-mediated gene transcription [31,32].
The effects of overexpressed MDM2 may be enhanced by
ER interactions with Sp1 [33]. These observations lend
further biological plausibility to the association between
MDM2 SNP309 and the development of endometrial can-
cer, a highly estrogen-dependent neoplasm. To date, a
number of epidemiological studies have evaluated the as-
sociation between MDM2 SNP309 polymorphism and
endometrial cancer risk, but the results remain inconclu-
sive. To derive a more precise estimation of relationship,
we performed this meta-analysis. Our meta-analysis based
on eight case–control studies suggested that the MDM2
SNP309 polymorphism contributes to increased endomet-
rial cancer susceptibility.
In the subgroup analysis by ethnicity, significantly in-
creased endometrial cancer risk was found in Caucasians.
However, no significant association was found in Asians.
It might not be uncommon for the same polymorphism
playing different roles in cancer susceptibility among dif-
ferent ethnic populations, because cancer is a complicated
multi-genetic disease, and different genetic backgrounds
may contribute to the discrepancy. Nevertheless, owing to
the limited number of relevant studies among Asian pop-
ulations included in this meta-analysis, the observed nega-
tive association between MDM2 SNP309 polymorphism
and endometrial cancer risk in Asians is likely to be
caused by chance because study with small sample sizes
may have insufficient statistical power to detect a slight ef-
fect or may have generated a fluctuated risk estimate. Cur-
rently there were only two studies [13,15] on MDM2
SNP309 polymorphism and endometrial cancer risk in
Asian populations, and the genotype distributions in the
control population of one study [13] was deviate from
HWE. Therefore, the negative results of the Asian popula-
tion should be interpreted with caution.
To clarify an association between genetic polymor-
phisms and cancer risk, the quality of the study design is
of great importance. In addition to controls that should
be in HWE, strict definitions of the study population,
appropriate materials used to assess genotype as well as
sufficient statistical power are required. Of the eigh eli-
gible studies, three were considered as low quality stud-
ies [11,13,18] and 5 were considered as high quality
studies [12,14,15,19]. When stratified according to the
quality of the articles, we found that the MDM2 SNP309
polymorphism was associated with elevated endometrial
cancer risk in both high and low quality studies in additive
model (CC vs. CG) and recessive model (GG vs. TG +TT). Interestingly, similarly elevated risks were found in
high quality studies, but not in low quality studies in the
dominant model (GG + TG vs. TT). Several possibilities
exist which may explain this finding, such as selection bias
and recall bias. Genotyping methods without quality con-
trol in low quality studies should be considered when
deciphering these inconsistent results, which reinforces
that the importance of precise methodologically design is
of great value in case–control studies.
It seemed that selection bias could have played a role
because the genotype distribution of the MDM2 SNP309
polymorphism among control subjects disobeyed the law
of HWE in one of the included studies [13]. It is widely
believed that deviation from HWE may be as a result of
genetic reasons including non-random mating, or the al-
leles reflect recent mutations that have not reached equi-
librium, as well as methodological reasons including
biased selection of subjects from the population or geno-
typing errors [34,35]. Because of the reasons of disequi-
librium, the results of genetic association studies might
be spurious if the distribution of genotypes in the con-
trol groups were not in HWE [36,37]. Hence, we carried
out subgroup analysis by HWE in controls. When ex-
cluding the study that was not in HWE, the results were
persistent and robust, suggesting that this factor prob-
ably had little effect on the overall estimates.
Heterogeneity is a potential problem when interpreting
the results of a meta-analysis, and finding the sources
of heterogeneity is one of the most important goals of
meta-analysis [38]. In the present meta-analysis, signifi-
cant between-study heterogeneity in the pooled analyses
of total eligible studies was observed in recessive model
GG vs. TG + TT (The PQ value was less than 0.001). To
find the sources of heterogeneity, we performed metare-
gression and subgroup analyses. Metaregression analysis
of data showed that the ethnicity, study quality, and
HWE status were the sources of heterogeneity. Sub-
group analyses stratified by ethnicity, study quality, and
HWE status showed that the heterogeneity was still sig-
nificant in Caucasians and studies consistent with HWE.
To further investigate the heterogeneity, Galbraith plots
analysis was performed to identify the outliers which
might contribute most to the heterogeneity. Our results
showed that the study of Zajac et al. [18] was the outlier
of recessive model GG vs. TG + TT in the overall popu-
lation, Caucasians, and studies consistent with HWE. All
I2 values decreased lower than 50% and PQ values were
larger than 0.10 after excluding the studies of Zajac et al.
[18] in the recessive model GG vs. TG + TT in the overall
population, Caucasians, and studies consistent with HWE.
However, the summary ORs for the MDM2 SNP309 poly-
morphism in recessive model GG vs. TG +TT in the
overall population, Caucasians, and studies consistent with
HWE were not material change by omitting this study,
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results indicated that the study of Zajac et al. [18] might
be the major source of the heterogeneity in the meta-
analysis.
Some limitations of this meta-analysis should be ad-
dressed. First, in subgroup analysis by ethnicity, the in-
cluded studies regarded only Asians and Caucasians.
Data concerning other ethnicities such as Africans were
not found. Thus, additional studies are warranted to evalu-
ate the effect of this functional polymorphism on endo-
metrial cancer risk in different ethnicities, especially in
Africans. Second, our results were based on unadjusted es-
timates. We did not perform the analysis adjusted for
other covariates such as age, obesity, drinking and smok-
ing status, menopausal status, use of contraceptives, envir-
onment factors, and so on, because of the unavailable
original data of the eligible studies.
In conclusion, this meta-analysis suggests that the
MDM2 SNP309 polymorphism may be associated with
increased risk of developing endometrial cancer particu-
larly among Caucasians. However, it is necessary to con-
duct large sample studies using standardized unbiased
genotyping methods, homogeneous endometrial cancer
patients, and well-matched controls. Moreover, gene–gene
and gene–environment interactions should also be consid-
ered in the analysis. Such studies taking these factors into
account may eventually lead to our better, comprehensive
understanding of the association between the MDM2
SNP309 polymorphism and endometrial cancer risk.
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